Datasheet

Bifidobacterium longum; BB536

Bifidobacterium longum was isolated from microbial inoculum. It is a Gram-positive, catalase-negative, rod-shaped bacterium. It is a microaerotolerant anaerobe and considered to be one of the earliest colonizers of the gastrointestinal tract of infants.

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

CAT	Size	Price	Quantity
LBST-056FG

Product Information
Product Overview	Bifidobacterium longum was isolated from microbial inoculum. It is a Gram-positive, catalase-negative, rod-shaped bacterium. It is a microaerotolerant anaerobe and considered to be one of the earliest colonizers of the gastrointestinal tract of infants.
Target	Bifidobacterium
Genus	Bifidobacterium
Strain Designation	BB536
Application	Study and research
Type Strain	No
Culture Medium	CM0787
Culture Conditions	37°C; Anaerobic
Source	Microbial inoculum
Characteristics	The thallus is rod-shaped, with Y-shaped bifurcation and Gram-positive.
Risk Group	1
Product Format	Freeze-dried
Packaging	Ampoule tube
Storage	-80°C
Shelf Life	6 years

Target Introduction
Introduction	Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS; Generally Recognised As Safe status.
Alternative Names	Bifidobacterium longum; BB536

Target Introduction

Introduction

Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS; Generally Recognised As Safe status.

Alternative Names

Bifidobacterium longum; BB536

Customer Reviews Related Products

Click the button below to contact us or submit your feedback about this product.

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.